Sy R K
Arch Otolaryngol. 1979 Nov;105(11):649-53. doi: 10.1001/archotol.1979.00790230019004.
A flunisolide-containing intranasal spray and matching placebo were used in an eight-week, double-blind parallel study in 67 patients with perennial rhinitis. Seventeen patients who did not benefit from treatment with the placebo then switched to flunisolide for a six-week open trial. Flunisolide-treated patients showed greater improvement in both duration and severity of symptoms, as well as a greater preference for flunisolide; 75% of patients either had "mild" symptoms or were asymptomatic and 67% stated that they experienced "substantial" or "total" control of symptoms. No serious side effects were encountered. Chief side effects in both drug and placebo groups were brief, mild, nasal burning and stinging on spray application. The drug exhibited no adverse effects on adrenal function (morning plasma cortisol levels).
一种含氟尼缩松的鼻喷雾剂和匹配的安慰剂用于一项针对67例常年性鼻炎患者的为期八周的双盲平行研究。17例未从安慰剂治疗中获益的患者随后改用氟尼缩松进行为期六周的开放试验。接受氟尼缩松治疗的患者在症状持续时间和严重程度方面均有更大改善，并且对氟尼缩松的偏好更高；75%的患者症状为“轻度”或无症状，67%的患者表示症状得到“显著”或“完全”控制。未出现严重副作用。药物组和安慰剂组的主要副作用均为喷雾使用时短暂、轻微的鼻内烧灼感和刺痛感。该药物对肾上腺功能（早晨血浆皮质醇水平）无不良影响。
